BAM
OVID icon

Blueshift Asset Management’s Ovid Therapeutics OVID Stock Holding History

Blueshift Asset Management’s Portfolio OVID Stock Details OVID Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q2 		– Sell
-34,706
Closed -$140K – 1104
2021
Q1 		$140K Buy
+34,706
New +$115K 0.01% 799

Other funds holding OVID

BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
AG
Artal Group Luxembourg $1.01B AUM 29.84% 1-Year Est. Return
SCM
Stonepine Capital Management Bend, Oregon $250M AUM 77.6% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
IC
Ikarian Capital Dallas, Texas $1.23B AUM 600.17% 1-Year Est. Return
GC
Globeflex Capital San Diego, California $661M AUM 50.59% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Blueshift Asset Management's OVID Position: Q2 2021 in Review

Blueshift Asset Management sold out of Ovid Therapeutics (OVID) in Q2 2021, closing a stake of 34,706 shares — an estimated $140K sold.

Blueshift Asset Management first reported a position in OVID in Q1 2021 and held it in 1 quarter. The position peaked at $140K in Q1 2021. 80 funds tracked by Wall St. Rank hold OVID as of Q2 2021.

  • Blueshift Asset Management reported no remaining Ovid Therapeutics position as of Q2 2021 after selling out during the quarter.
  • Blueshift Asset Management sold 34,706 Ovid Therapeutics shares in Q2 2021, an estimated $140K.
  • Blueshift Asset Management first reported a position in Ovid Therapeutics in Q1 2021 and held it in 1 quarter.
  • Blueshift Asset Management's Ovid Therapeutics position peaked at $140K in Q1 2021.
  • 80 funds tracked by Wall St. Rank held Ovid Therapeutics as of Q2 2021.

Based on Blueshift Asset Management's 13F filing for Q2 2021, filed 13 Aug 2021.